-

Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Dr. Reginald Seeto and William S. Solari III to its Board of Directors.

"Their guidance will be instrumental as we advance key clinical milestones and unlock the full potential of our pipeline," said Cheng Liu, Ph.D., Founder and CEO of Eureka Therapeutics.

Share

Dr. Seeto is a global leader in biopharmaceuticals and diagnostics with expertise in corporate strategy, business development, and operations. He currently serves as President and CEO of Scipher Medicine. Previously, he was President and CEO of CareDx, Inc., guiding the company through a period of rapid growth. He served as Chief Operating Officer at Ardelyx, where he built international partnerships to support commercialization, and held senior leadership roles at AstraZeneca, where he completed over 100 biologics transactions and managed portfolio strategy for more than 150 assets. His earlier career includes McKinsey & Company, Boehringer Ingelheim, and Organon.

Mr. Solari brings over 30 years of legal and financial experience in corporate governance, mergers and acquisitions, and complex tax structuring. He was a partner at Jeffer Mangels Butler & Mitchell LLP before founding his own law practice, where he continues to advise clients across diverse industries.

“Reg and Bill bring exceptional leadership and strategic insight to our Board,” said Cheng Liu, Ph.D., Founder and CEO of Eureka Therapeutics. “Their guidance will be instrumental as we advance key clinical milestones and unlock the full potential of our pipeline.”

ABOUT EUREKA THERAPEUTICS, INC.

Eureka’s proprietary ARTEMIS® CAR-T platform is designed to overcome key limitations of conventional CAR-T therapies by reducing toxicity to enable higher doses and repeat infusions, improving T-cell persistence for longer-lasting responses, and enhancing tumor infiltration to achieve more potent anti-tumor activity. Eureka’s pipeline includes ET140203 (ARYA-2) for pediatric patients and ECT204 (ARYA-3) for adults, both in Phase I/II clinical trials for advanced liver cancer.

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information, please visit www.eurekatherapeutics.com.

Contacts

Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com

Industry:

Eureka Therapeutics, Inc.

Release Versions
English

Contacts

Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com

Social Media Profiles
Eureka Therapeutics
Eureka Therapeutics
Eureka Therapeutics
More News From Eureka Therapeutics, Inc.

U.S. FDA Grants RMAT Designation to ECT204, an ARTEMIS® CAR (AbTCR) T-Cell Therapy for Advanced Hepatocellular Carcinoma

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company advancing next-generation T-cell therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ECT204, a GPC3-targeting ARTEMIS® CAR T-cell therapy, for the treatment of patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. The RMAT designation followed the F...

Eureka’s ARTEMIS® CAR T Cells Show Breakthrough Potential in Solid Tumors in NCI-Led Study Published in Cell Reports Medicine

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies for cancer, today announced the publication of a peer-reviewed study titled “Antibody–Gamma/Delta T Cell Receptors Targeting GPC2 Regress Neuroblastoma with Low Antigen Density” in Cell Reports Medicine. The study, led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, demonstrated that Eureka’s ARTEMIS® CAR T cel...

Eureka Therapeutics Adds Stanford Liver Cancer Expert Dr. Samuel So to Scientific Advisory Board

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Samuel So, MBBS, FACS, a globally recognized leader in liver cancer surgery, prevention, and health policy at Stanford University, to its Scientific Advisory Board. Dr. So will provide strategic guidance as Eureka advances its ARTEMIS® CAR-T platform and clinical programs targeting hepatocellular carcinoma...
Back to Newsroom